National focus (n) | Medical focus (n) | News actors (n) | Appeals (%)** | Credibility (%) | Risks (%) |
---|---|---|---|---|---|
India – 26 | Cosmetic surgery – 20 | Patient – 69 (F: 58; Au: 63) | Access to services (except for reasons of cost) – 62.1 | Use of personal testimonials – 50.0 | Ethical dilemmas – 53.0 |
Malaysia – 12 | Stem-cell therapy – 15 | Low cost – 36.4 | Reference to number of international patients – 42.4 | Uncertainty as to what is on offer – 50.0 | |
Thailand – 10 | Reproductive therapies – 13 | Expert – 68 (Au: 36) | Ability to ‘feel good’ – 21.2 | Logo/branding symbol −19.7 | Complications – 34.8 |
The Philippines – 6 | Transplant surgery – 9 | Medical tourism facilitator/representative of overseas hospital – 26 (Au: 2) | Access to ‘medical breakthrough’ – 21.2 | Mention of international accreditation – 12.1 | Procedural risk – 22.7 |
China – 5 | Reconstructive surgery – 4 | Family member/carer – 22 (F: 6) | Travel opportunity −16.7 | Surgeon/practitioner biography or education – 10.6 | Post-operative care – 12.1 |
Pakistan and Russia – 2 each | Orthopaedic surgery – 3 | Kidney donor – 13 (F: 3) | High-quality services – 13.6 | Ease of contacting practitioner post-procedure – 6.0 | Lack of legal recourse – 10.6 |
‘Asia’ in general – 2 | Novel, drug-resistant infection – 2 | Surrogacy client – 10 (F: 5; Au: 8) | No waiting time – 13.6 | Exposure to novel risks – 9.1 | |
No country named – 3 | Other – 3 | Other – 7 (Au: 5) | State-of-the-art facilities – 12.1 | Difficulty in contacting practitioner post-procedure – 4.5 | |
‘Vox pop’/audience member – 6 (Au: 6) | Surgeon/practitioner expertise – 10.6 | ||||
Government spokesperson or official – 4 (Au: 0) | Personalised service – 10.6 | ||||
Politician – 4 (Au: 2) | Access to latest technology – 4.5 | ||||
Surrogate mother – 3 (Au: 1) | Greater convenience – 1.5 |